Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI

Christin Y. Sander, Jacob M. Hooker, Ciprian Catana, Marc D. Normandin, Nathaniel M. Alpert, Gitte M. Knudsen, Wim Vanduffel, Bruce R. Rosen, and Joseph B. Mandeville

This study employed simultaneous neuroimaging with positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) to demonstrate the relationship between changes in receptor occupancy measured by PET and changes in brain activity inferred by fMRI. By administering the D2/D3 dopamine receptor antagonist [11C]raclopride at varying specific activities to anesthetized nonhuman primates, we mapped associations between changes in receptor occupancy and hemodynamics in the dopamine-rich striatum. Moreover, similar temporal profiles were observed for specific binding estimates and changes in cerebral blood volume (CBV). Injection of graded raclopride mass doses revealed a monotonic coupling between neurovascular responses and receptor occupancies. The distinct CBV magnitudes between putamen and caudate at matched occupancies approximately matched literature differences in basal dopamine levels, suggesting that the relative fMRI measurements reflect basal dopamine receptor occupancy. These results provide a basis for models that relate dopaminergic occupancies to hemodynamic changes in the basal ganglia. Overall, these data demonstrate the utility of simultaneous PET/fMRI for investigations of neurovascular coupling that correlate neurochemistry with hemodynamic changes in vivo for any receptor system with an available PET tracer.

dynamic binding potential | displacement | monkey | NHP

The neural basis of functional magnetic resonance imaging (fMRI) signals has been a topic of extensive investigation. Experimental correlations of fMRI signals or cerebral blood flow with relative changes in glucose or oxygen utilization (1–3) have been performed to determine whether hemodynamic responses reflect a coupling with metabolism—a hypothesis with a long history (4). To relate hemodynamic responses more directly to neural circuitry, fMRI or optical imaging signals have been correlated with electrophysiology, using graded levels of stimulation in preclinical models (5–7). These results generally demonstrate a monotonic coupling between electrical activity and evoked cortical hemodynamic responses, using sensory stimuli. However, the methodology is not readily extensible to human subjects, and the implications of such studies are difficult to generalize to pharmacotherapies or other drug stimuli that target specific neurotransmitter systems.

Recent technological advances in multimodal imaging have enabled the simultaneous acquisition of MRI and positron emission tomography (PET) data (8). One of the motivations for conjointing these modalities was the potential for new insights into neural function based upon the complementary natures of PET and fMRI. In activation paradigms, fMRI provides excellent spatio-temporal resolution for localizing changes in brain activity but offers little insight into the underlying neurotransmission. Conversely, although PET has more limited temporal and spatial resolution for functional measurements, it offers high sensitivity and neurochemical specificity. Together, PET and MRI measures have the potential to help clarify the neurochemical basis of changes in fMRI signal induced by selective exogenous ligands or endogenous neurotransmitter. Perhaps because combined PET/MRI systems have become available only recently, there have been no reports to date that have dynamically compared the functional output reported by fMRI with in vivo occupancy for any neuroreceptor system targeted by a selective ligand.

The dopamine (DA) system has been a primary target of PET studies due to its role in numerous diseases, including Parkinson disease, schizophrenia, and behaviors related to natural rewards and drug abuse. The basal ganglia present an ideal target system for initial PET/MRI studies of neurovascular coupling, because this system has been studied widely in humans and nonhuman primates (NHPs), using PET radiotracers that have been thoroughly characterized (9). fMRI signals strongly correlate with evoked DA in rodents under some circumstances (10), suggesting that DA is driving the fMRI response. Stimulation of D2/D3 dopamine receptors (D2/D3R) produces inhibition of basal ganglia in fMRI studies in rodents (11, 12). This finding is consistent with G-protein-coupled pathways leading to D2/D3R-mediated inhibition of adenylate cyclase and cyclic AMP, a second messenger in the ATP pathway leading to energy production (13).

In this study, responses of the dopaminergic system in NHPs were assessed with PET/fMRI to characterize the dynamic relationship between hemodynamic responses and changes in neurochemistry. The PET ligand [11C]raclopride (RAC), a selective D2/D3R antagonist, was administered at decreasing specific activities (i.e., increasing total mass doses) to evoke fMRI responses. The latter were compared to receptor occupancy measures from PET in the domains of time, space, and dose. Thereby, we test the hypothesis that fMRI signal changes are correlated with DA displacement in each of these domains. This study initiates a new methodology for investigating neurovascular/neurochemical coupling in health and disease, using simultaneous PET/fMRI.

Results

Fig. 1 demonstrates the basic paradigm and hypothesis employed in this study. With a very low mass of [11C]RAC, the PET signal is sensitive to available D2/D3R in the baseline state (Fig. L4). Due to much higher density of D2R relative to D3R in caudate and putamen (14), [11C]RAC-specific binding is highly weighted by D2R density in these regions. We hypothesize that increasing
masses of nonradioactive RAC (decreasing specific activities) displace progressively more DA, reducing PET binding at D2/D3R, while invoking an fMRI signal (Fig. 1B). This is illustrated in the temporal domain by simulations of a two-tissue compartmental model (Fig 1C): The wash in/wash out of RAC causes a time-dependent displacement of basal DA from D2/D3R and a reduction of available D2/D3R. However, pharmacokinetics largely dictate the shape of time-dependent changes in specific binding, which differs only subtly vs. mass until high occupancies in simulations (Fig. S1 and Table S1).

Experimental PET time-activity curves (TACs) from five injections of [11C]RAC with different specific activities in one NHP [male rhesus macaque 1 (M1)] are shown in Fig. 1D for whole putamen and normalized to peak activity, together with the low-mass cerebellum TAC as a reference. As the total injected mass of RAC increases, unlabeled RAC occupies progressively more binding sites and thus reduces specific binding by labeled RAC, so that putamen TACs start to resemble the shape of the nonspecific (cerebellum) TAC.

Kinetic Modeling Results. We hypothesized that changes in RAC-specific binding are related to fMRI responses under the assumption that DA displacement drives the fMRI signal. Hence, we employed two analyses within the simplified reference tissue model (SRTM) framework (15): (i) a conventional steady-state binding potential [binding potential (nondisplaceable) (BPND)] analysis and (ii) an analysis based upon “dynamic binding potentials”, DBPND(t), as defined in Eq. 3 in Materials and Methods, to compare peak changes in PET binding with peak changes in fMRI signal.

Kinetic model fits are illustrated in Fig. 2 for three different RAC mass doses in M1. Dynamic analyses (Fig. 2 B and C) reduced the chi-square per degree of freedom (χ2/DOF) and Akaike information criterion measures for all fits. Representative curve fits comparing the SRTM and dynamic analysis are shown in Fig. S2. Moreover, dynamic analyses of forward-model simulations determined that DBPND peak consistently produced good agreement with true peak occupancies (Fig. S3), whereas analyses based upon BPND did not consistently reflect peak or average occupancies across all mass doses. For the low-mass RAC dose, DBPND peak values from both animals averaged 4.2 ± 1.3 in putamen and 3.8 ± 1.5 in caudate, while BPND values averaged 4.3 ± 1.8 in putamen and 4.1 ± 1.9 in caudate. Average R1 and k2 parameters from the DBPND analysis were 0.93 ± 0.08 and 0.27 ± 0.30, respectively.

Temporal Correlation. Temporal responses from fMRI for whole putamen are shown in Fig. 3A and B for the two highest-injected masses of RAC in one animal and are overlaid with approximations of specific binding (S = C1 − R1CREF), derived directly from PET TACs. Using this specific binding estimate allowed a direct temporal comparison of responses derived from PET and fMRI data. S provides a reasonably accurate index of specific binding as modeled with a two-tissue compartmental model (Fig. S4). The time courses of PET-specific binding estimates and fMRI responses resembled each other, as time-to-peak measures and durations were similar.

Fits to the fMRI temporal response and DBPND(t) were determined by varying the time-to-peak (τ) of gamma-variate regressors (τi · e−τ) to optimize the goodness of fit to the data within the general linear model (GLM). For both fMRI and PET data, χ2/DOF values were slowly varying functions of the time to peak. All χ2/DOF increases by less than 10% across a 4-min window centered upon the optimal value. Optimal time-to-peak values from fMRI and PET analyses differed by less than 4 min for each animal at the two highest doses, for which the fMRI signal was robust.

Spatial Correlation. Fig. 4, Upper shows parametric DBPND peak maps from PET for four mass doses, and Fig. 4, Lower shows the corresponding fMRI maps in units of percentage of cerebral blood volume (%CBV). A P-value threshold of P<0.03, computed with a mixed-effects model (16) across two animals, was applied to all CBV maps. For the lowest RAC mass, the DBPND maps exhibited high specific binding and a high binding potential in the striatum, but hardly any detectable fMRI signal. In the voxelwise maps, 49% of voxels within the putamen were above a value of DBPND peak and 25% within the putamen exceeded a value of DBNDBPND peak. Results were reversed for the highest RAC mass dose, for which binding potential was very small, whereas fMRI reported a large positive change in CBV. The peak CBV response relative to baseline CBV averaged 9.8% ± 3.5% across whole putamen and 4.3% ± 1.7% across caudate. Voxelwise analysis showed that 45% of voxels within the putamen showed CBV>8% and 19% of voxels in putamen recorded CBV>12%.

The high-binding regions of the striatum and the neurovascular responses were remarkably similar on the voxel-wise maps (Fig. 4). As mass dose increased, the specific binding signal in the striatum decreased visibly in the parametric DBPND maps, whereas CBV increased from no detectable signal to a prominent signal within the striatum.

Occupancies and Relationship to fMRI. Table 1 lists values for BPND, DBPND peak, steady-state RAC occupancies θRAC, and peak occupancies θRAC (Eq. 4) for whole putamen from the SRTM and the dynamic binding analysis, together with peak changes in

![Figure 1](image1.png)  
**Fig. 1.** Schematic illustrating the basic PET/fMRI paradigm. (A) [11C]RAC binds specifically to available D2/D3R in the baseline state. (B) Antagonism at D2/D3R causes a positive fMRI signal, whereas unlabeled RAC competes with [11C]RAC, decreasing the PET signal. (C) Simulations show the dynamics of RAC and DA occupancy at D2/D3R, together with available D2/D3R, all expressed as a percentage of total D2/D3R. (D) Experimental results show changes in the shape of PET TACs for whole putamen, normalized to peak, in order of increasing RAC mass dose (solid line to lines with light shading) and a low-mass cerebellum TAC (dashed line).
CBV for each RAC mass dose for both animals. $BP_{ND}$ extrapolated to true zero occupancy for whole putamen were 3.5 and 5.0 for NHPs M1 and M2, respectively. These were computed from five (M1) or four (M2) RAC mass doses with the Hanes–Woelfl plot, in which $1/BP_{ND}$ is plotted vs. free ligand concentration in tissue. The latter was estimated from specific activity values and the first 60 min of data from the cerebellum TAC. On the basis of these extrapolated baseline binding potentials, occupancies for whole putamen ranged from ~7% to 91% for M1 and from <1% to 82% for M2. The average RAC dissociation constant $K_d$ across animals was $1.9 \pm 0.6$ nM (assuming a RAC free fraction, $f_{ND} = 0.12$ (17)), which is within the range of literature values (18).

Fig. 5 A and B shows the relationship between peak RAC occupancies and peak %CBV changes for whole putamen and caudate in each animal. Data points were described by regression with a power law with two parameters: $a \cdot (\theta_{RAC})^b$. For M1, the exponent $b$ was 1.7 and 1.4 in putamen and caudate, respectively, with $R^2$ values of 0.97 and 0.39. For M2, the corresponding exponents were 1.4 and 1.6, with $R^2$ values of 0.99 and 0.88. The regression with a power fit is concordant with a model describing the relationship between DA and RAC occupancy (Eqs. S1 and S2). If we assume a twofold increase in extracellular DA due to RAC injection, model calculations and a corresponding power law fit predict an exponent of $b = 1.6$ (Fig. S5), which agrees with our experimental data.

From a regional analysis, we found that CBVpeak responses from the putamen region of interest (ROI) were much larger compared to caudate in both animals (Fig. 5). The putamen/ caudate ratio of the CBVpeak response at 80% occupancy, estimated from the experimental data fit, was $2.2 \pm 0.2$. Including the fitted CBVpeak values for all occupancies between 50% and 100%, the average putamen/caudate ratio was $2.2 \pm 1.7$. Regional differences in receptor densities were 9% ± 2% less in caudate, as determined by baseline $BP_{ND}$ values. These density differences alone do not provide an explanation for the much smaller functional response in caudate.

We conclude that there is a monotonically increasing relationship between RAC occupancy and changes in %CBV that showed a good fit to a superlinear function. Moreover, the magnitude of the CBV response for all RAC masses exhibited a regional dependence within the striatum.

Discussion

In this study, we investigated the relationship between neurovascular responses and receptor occupancies, using simultaneous PET/fMRI and variable mass doses of the D2/D3R antagonist RAC. As injected RAC mass dose was increased, the reduction in $[^{11}C]$RAC-specific binding correlated with CBV increases in the striatum spatially and temporally with RAC mass dose. These data suggest that vascular responses to D2R-like antagonists are coupled to changes in neuroreceptor occupancy.

By directly comparing changes in neuroreceptor occupancy with a simultaneously induced functional response, we demonstrated an approach that can be employed widely using both antagonists and agonists. This opens up the possibility of probing mechanisms of neurovascular coupling or investigating brain circuitry by relating selective neuroreceptor binding to local and distant functional responses. Studies of this design can be used to develop multireceptor models that describe the fMRI response to endogenous neurotransmitter (19) to clarify the neurochemical basis of behaviors like reward (20, 21). Finally, simultaneous PET/fMRI studies using targeted PET ligands may provide information about basal receptor occupancy, a quantity that is not routinely measured by PET alone.

Regional Dose Response. The maps of $BP_{ND}$ and %CBV in Fig. 4 each showed localized signals in striatal regions that exhibited a strong dependence on injected RAC mass. At low injected masses, $BP_{ND}$ maps showed high specific binding indicative of a large number of available receptors in basal ganglia, as expected. At high RAC masses, specific binding of $[^{11}C]$RAC was decreased by competition with unlabeled RAC. However, fMRI showed progressively larger increases in CBV at higher-mass doses that presumably reflect transient decreases of DA basal occupancy at D2/ D3R. Because DA produces an inhibitory effect at D2/D3R, an explanation for the increase in CBV is that RAC blocks the inhibitory effect of DA upon D2/D3R. Thus, fMRI responses were observed predominantly in regions with high D2/D3R density.

Temporal Comparisons. The temporal response of the fMRI signal closely matched the kinetics of $[^{11}C]$RAC-specific binding estimates (Fig. 3). The temporal correlation is intriguing given the numerous physiological mechanisms that could cause temporal responses from the two modalities to diverge. For instance, a large dose of an agonist might promote receptor internalization. This mechanism has been suggested to explain the prolonged decrease in raclopride displacement following infusion of a large dose of amphetamine (22). With internalization, fMRI signal should be shortened in time, so that divergent temporal responses could offer insight into dynamic physiological adaptations like agonist-induced receptor internalization. However, our data show that a D2/D3 antagonist produces changes in binding potentials and fMRI signals that are well matched in time, which is consistent with a classical competition model (22) between RAC and DA for synaptic binding sites.

Neurovascular Coupling Mediated by D2/D3R Antagonism. In this study, data showed a monotonically increasing relationship between changes in CBV and RAC occupancies in subregions of basal ganglia. A postulate of linearity between tissue function and receptor occupancy was proposed as early as 1937 (23). For
pharmacological stimuli, receptor occupancy is an important synaptic quantity that underlies the genesis of a functional response. Moreover, correlations between hemodynamics and electrophysiology have shown that vascular responses are monotonically related to integrative synaptic quantities like local field potentials and multiunit activity (5–7, 24).

As a basis for discussion of the observed CBV-occupancy relationship, we propose a model for the fMRI response: CBV changes (ΔCBV) are driven by relative changes in receptor occupancies (Δθ) and are scaled by ligand efficiencies (ε), the local density of receptors (Bmax), and excitatory/inhibitory neurovascular coupling constants (N). In a general framework, CBV changes due to exogenous or endogenous agonists reflect the sum of influences mediated by multiple receptor subtypes:

\[
ΔCBV = \sum_{i,j} N_i B_{\text{max},i} Δθ_{j}.
\]  

[1]

Antagonists like RAC have affinity but no efficacy at target receptors. However, RAC produces a physiological response by displacing DA. As a first step, we adopt a first-order (linear) approximation for our results that ignores any additional DA release (\(Δθ_{\text{DA}} = -θ_{\text{RAC}}\theta^{(0)}_{\text{DA}}\); Eq. S3 and Fig. S5) and Eq. I simplifies to

\[
ΔCBV = -N_2 B_{\text{max},2} \theta^{(0)}_{\text{DA}} θ_{\text{RAC}}.
\]  

[2]

This description relates a positive ΔCBV to RAC occupancy, basal DA occupancy, and Bmax via an inhibitory N2.

The precise nature of the relationship between θRAC and the change in DA occupancy should be dependent on the magnitude of additional DA release induced by the binding of RAC to presynaptic autoreceptors (25). A classical competition model predicts that changes in fMRI signal are insensitive to DA release at very high RAC occupancies. At moderate occupancies, increased synaptic DA will more effectively compete with RAC, causing the relationship between DA and RAC occupancies to become superlinear (Fig. S5). This effect may explain the superlinear correlation between RAC occupancy and CBV in Fig. 5.

### Basal Dopamine Occupancy.

As observed from the CBV-occupancy plot (Fig. 5), caudate exhibited a remarkably smaller CBV increase than putamen with pharmacologic doses of RAC. The proposed coupling model from the previous section provides a potential explanation for this difference by showing that both receptor density and basal D2/D3R occupancy affect the CBV response. We can apply Eq. 2 to calculate the ratio of basal D2/D3R occupancy between putamen and caudate on the basis of our study data: Taking into account a small difference in receptor densities from our PET measurements (% fewer receptors in caudate), this ratio is 2.0. Several studies have measured higher levels of basal DA in putamen compared to caudate, using microdialysis in NHPs in vivo (26, 27), with basal DA levels up to 2-fold higher in the putamen. Further evidence of higher basal D2/D3R occupancy in putamen is provided by human post-mortem (28) and PET studies with basal DA depletion (29); both methods showed a 1.3- to 1.5-fold difference. Conversely, some studies indicate similar levels of basal DA or basal D2/D3R occupancy in putamen/caudate (30–32). Our results suggest that PET/fMRI measurements of this type offer the potential to noninvasively assess relative differences in basal neurotransmitter occupancy across regions or ultimately across subject groups.

### Study Limitations.

There are a number of limitations with this animal model. Studies were performed in isoflurane-anesthetized NHPs to facilitate the use of pharmacological challenges that achieved very high occupancies. Hence, changes in basal DA induced by anesthesia could potentially affect the magnitude of fMRI signal changes in this paradigm. Very high levels of isoflurane (3%) increase basal DA in rats, but effects are not significant at 1% isoflurane (33), as used in this study. In some experiments, we observed large, transient, and repetitive changes in fMRI signal that were consistent with isoflurane-induced burst suppression, a noise source that would not be present in human studies. Additionally, we employed an MRI contrast agent that increases the magnitude of fMRI signal changes. With endogenous contrast techniques, it may be difficult to detect small signal changes due to pharmacological stimuli. The MR contrast agent now has been used for fMRI in human subjects (34), although repeated within-subject measurements presumably would be restricted.

There are also limitations to our interpretation of D2/D3R-mediated neurovascular coupling. Our results and proposed model are consistent with a neurovascular coupling mechanism that is driven by occupancy as one aspect of synaptic processes. However, we cannot exclude direct actions of DA on the vasculature that are uncoupled with neural activity. Our model excludes other factors (e.g., neurotransmitter release) that also

---

**Table 1. Summary of parameters and outcomes of the PET/fMRI paradigm for putamen in two animals (M1 and M2)**

<table>
<thead>
<tr>
<th>Study parameters and outcomes</th>
<th>Dose 1</th>
<th>Dose 2</th>
<th>Dose 3</th>
<th>Dose 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injected RAC mass, μg/kg</td>
<td>0.3</td>
<td>0.3</td>
<td>4.5</td>
<td>4.5</td>
</tr>
<tr>
<td>Specific activity, μCi/nmol</td>
<td>1,350</td>
<td>1,350</td>
<td>53</td>
<td>53</td>
</tr>
<tr>
<td><strong>Study outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BPND</td>
<td>3.0</td>
<td>5.6</td>
<td>5.1</td>
<td>5.1</td>
</tr>
<tr>
<td>DBPmax</td>
<td>3.3</td>
<td>5.6</td>
<td>1.6</td>
<td>2.4</td>
</tr>
<tr>
<td>RAC occupancies (^1) θRAC, %</td>
<td>0</td>
<td>0</td>
<td>40</td>
<td>43</td>
</tr>
<tr>
<td>Peak RAC occupancies (^1) θRAC, %</td>
<td>0</td>
<td>0</td>
<td>50</td>
<td>52</td>
</tr>
<tr>
<td>Peak ΔCBV, %</td>
<td>0.5±0.3</td>
<td>−1.1±0.4</td>
<td>2.2</td>
<td>5.8</td>
</tr>
</tbody>
</table>

\(^1\) Occupancies are computed relative to dose 1.

\(^2\) Average CBV from repeated studies.

---

**Fig. 5.** (A and B) %CBV\(^\text{max}\) vs. occupancy can be approximated by a power-law fit (with exponent b) for putamen and caudate ROIs for M1 and M2. Data show a monotonically increasing relationship, with putamen exhibiting approximately twice the CBV magnitude compared to caudate. Error bars show within-session uncertainty from the GLM analysis and SEM for repeated fMRI studies with the lowest RAC mass dose.
could contribute to neural activity and changes in fMRI signal. Moreover, neural pathways that project to a region of interest may produce functional contributions that are not directly related to local occupancy, although such situations can provide useful information about neural connectivity.

Within the framework of an occupancy-based model like Eq. 1, there are potential contributions to the fMRI response other than changes in D2/D3R occupancy. We assumed a linear relationship between DA occupancy and fMRI signal, together with a super-linear relationship between RAC and DA occupancies. Although this model produces good agreement with data, there is no routine way to measure DA occupancy directly to verify the linear assumption of Eq. 1. Additionally, RAC-mediated DA release can cause a positive fMRI signal contribution due to stimulation of D1-like excitatory receptors. To address this issue quantitatively, further studies will be needed to clarify the magnitude of fMRI signal changes associated with changes in D1 occupancy.

**Potential Clinical Applications.** Clinically, simultaneous PET/fMRI appears to have broad roles for diagnosis and monitoring of therapy (35). On the basis of this study, one potential application is the estimation of basal receptor occupancies, which are coupled to basal neurotransmitter levels. Basal occupancies are not routinely measurable by PET alone unless neurotransmitter is fully depleted from the brain. DA depletion studies have employed PET to assess differences in basal D2/D3R occupancy in patient and control populations (36). Although such studies have helped clarify important aspects of basal DA function, depletion can produce motor dysfunction and “a whole spectrum of psychiatric symptoms” (ref. 37, p. 1755). Other methodological concerns include incomplete depletion and receptor externalization or up-regulation (38). More tolerable methods for assessing basal occupancy might facilitate the identification of therapeutic correlates of basal occupancy, following paths established for D2/D3R occupancy by antipsychotics (39).

In this PET/fMRI study, the DA-bound receptor population was unmasked transiently by antagonist displacement rather than by depletion. If studies demonstrate sufficient reproducibility/specificity, a single injection of an antagonist could in principle provide a relative index of basal occupancy for use in cross-sectional studies. D2/D3R antagonist doses would need to produce measurable fMRI signals in humans while avoiding the noxious side effects that accompany occupancies above the “therapeutic window” of 70–80% for antipsychotics (40).

**Conclusions**

We demonstrated an imaging methodology in which a PET antagonist can be administered at pharmacologic doses to measure neurovascular responses simultaneously with receptor occupancy. By measuring cerebral responses using different specific activities of $[^{11}C]$raclopride with PET/fMRI, we observed that the signals from both modalities correlated in anatomical and temporal domains. Our results suggest a monotonic coupling relationship between neurovascular responses and dopamine D2/D3R occupancy in basal ganglia across a wide dynamic range. We observed distinct relative CBV magnitudes between putamen and caudate, consistent with higher basal dopamine levels in putamen. These results demonstrate that the concurrent assessment of hemodynamics and receptor-specific neurotransmission with simultaneous PET/fMRI offers unique possibilities for performing dynamic neurotransmitter mapping and understanding distributed functions of the brain in preclinical and clinical studies.

**Materials and Methods**

**Animal Studies.** Two male rhesus macaques, M1 (7 y) and M2 (5 y) with mean weight of 11.7 kg and 7.5 kg underwent imaging. Anesthesia was induced with ketamine (20 mg/kg ketamine with 0.4 mg/kg diazepam or 10 mg/kg ketamine with 0.5 mg/kg xylazine), and a catheter for injections was placed in the saphenous vein. During scans, anesthesia was maintained by isoflurane (0.8–1.5%, mixed with pure oxygen) through an intubation tube without ventilation. Physiological changes (blood pressure, pulse, end-tidal CO$_2$, and breathing rate) were monitored continuously throughout the experiment. The procedures complied with the regulations of the Subcommittee on Research Animal Care at Massachusetts General Hospital. 

**Study Design.** Four different RAC mass doses were administered by bolus injection to two animals (Table 1). Injections of high-mass doses of RAC were separated by at least 2 wk. Additionally, five low-mass dose studies (three with M1 and two with M2) were acquired to compute average low-dose fMRI signals. An additional mass dose of RAC (1.4 µg/kg) was administered to M1 during a PET-only scan and used in the $K_{DO}$ computation for M1. For each scan, 4.6–6.6 mCi of $[^{11}C]$raclopride was administered intravenously over ~30 s. $[^{11}C]$raclopride was synthesized from the O-desmethyl RAC precursor and $[^{11}C]$methyl iodide. The synthesis and subsequent purification by high-performance liquid chromatography were performed according to ref. 41 with minor modifications. To vary the specific activity and total mass for the five studies, unlabeled RAC was added after synthesis to the saline formulation to obtain the specific activities in Table 1.

**PET/fMRI Image Acquisition.** Simultaneous dynamic PET/fMRI scans were acquired on a research-dedicated human PET/MR scanner, which consists of a 3 T MRI scanner (MAGNETOM Trio, Tim system; Siemens AG, Healthcare Sector) and an MR-compatible PET insert (BrainPET; Siemens AG, Healthcare Sector). A vendor-supplied circularly polarized local transmit birdcage coil with an eight-channel receive array was used for MR imaging in animal M1. A smaller, more sensitive custom-built eight-channel NHK receive array was used for imaging animal M2. The phased-array receivers enabled a twofold acceleration with GRAPPA (42) in the anterior–posterior direction to reduce the echo time (TE) (TE = 23 ms) and image distortions during fMRI. We employed multislice echo-planar imaging with whole-brain coverage and an isotropic resolution of 1.3 mm (MR field of view = 110 × 72.8 mm$^2$, bandwidth = 1,350 Hz/pixel) with a temporal resolution (TR) of 3 s. Prior to fMRI, femur-oxygen (Feraheme; AMAG Pharmaceuticals) (43) was administered intravenously at 10 mg/kg to improve fMRI detection power (44). Dynamic acquisition of fMRI images started ~20 min before RAC injection and lasted ~90 min in total. PET emission data were acquired in list-mode format for 90 min starting with ligand injection and sorted in the line-of-response space. Images were reconstructed with the ordinary Poisson expectation maximization algorithm with 32 iterations. With the PET camera used in this study, the highest image resolution was on the order of 2–3 mm (45). Corrections for scatter and attenuation of the head and the radiofrequency coil were applied during reconstruction as described in ref. 46. The final reconstructed volume consisted of 76 slices with 128 × 128 pixels (2.5-mm isotropic voxels), with framing intervals of 10 × 30 s, followed by 85 × 1 min.

**fMRI Data Analysis.** fMRI (and PET) data were registered to the Saleem–Logothetis stereotaxic space (47), using a population-averaged MRI-based template for rhesus monkey brain (48). Prior to statistical analysis using the GLM, fMRI data were spatially smoothed with a 2.5-mm Gaussian kernel to correspond approximately to the PET resolution. A gamma-variate function modeled the fMRI temporal response to RAC infusion. The time-to-peak response of the gamma function was adjusted to minimize the $R^2$/DOF of the GLM fit to data for mass doses 2–4 (Table 1). The specific binding signal from PET defined the time to peak for the lowest-mass dose, which did not produce observable changes in fMRI signal. Maximum changes in fMRI signal were defined as peak magnitudes of the gamma-variate regressor scaled by the GLM. These values were converted to changes in %CBV, using standard methods (49).

**PET Data Analysis.** By convention, $BP_{ND}$ is defined at steady-state concentration (50) under the assumption that specific binding has no time dependence. However, binding is not constant in time in this (Fig. 1) or other challenge protocols, so that it is unclear how $BP_{ND}$ relates to dynamic fMRI measures. Nevertheless, we report $BP_{ND}$ values, using a conventional analysis to facilitate literature comparisons. Additionally, we employed an alternative analysis that explicitly incorporates time dependence into occupancy estimates and allows the comparison of peak occupancy with peak CBV measures. We thus defined a related binding-dependent quantity, the dynamic binding potential, $DBP_{ND}(t)$:

$$DBP_{ND}(t) = \frac{R(t) - k_2(t)}{k_{2a}(t)} - 1.$$ 

$DBP_{ND}(t)$ was determined using a time-dependent parameter $k_{2a}(t) = k_{2a} + k_{3a}(t/e^{1-t/\tau})$ from the STRM (51, 52). This enabled computation of peak occupancies.
Supporting Information

Sander et al. 10.1073/pnas.1220512110

Relationship Between Raclopride and Dopamine Occupancies

Raclopride (RAC) competes with dopamine (DA) for binding to D2/D3 dopamine receptors (D2/D3R), such that increasing doses of RAC displace progressively more DA. To establish an approximate relationship between these occupancies, we assume transient equilibrium conditions, which are applicable at the peak response of RAC occupancy. Moreover, we assume that the nondisplaceable tissue-free fraction of [1^14C]RAC stays constant. Because the onset rate constant is a function of the available receptor pool \(k_3 = k_{on,B_{max}}\), the equilibrium condition can be written as (1)

\[
(B_{max} - B_{DA} - B_{RAC}) \theta_{DA} = K_{D,DA} B_{DA},
\]

where

\[
K_{D,DA} = \frac{k_{off,DA}}{k_{on,DA}},
\]

or

\[
\theta_{DA} = (1 - \theta_{RAC}) \frac{F_{DA}}{F_{DA} + K_{D,DA}}, \quad \text{[S1]}
\]

with

\[
\theta_{DA} = \frac{B_{DA}}{B_{max}} \quad \text{and} \quad \theta_{RAC} = \frac{B_{RAC}}{B_{max}}.
\]

\(B_{max}, B_{DA},\) and \(B_{RAC}\) refer to the total number of D2R receptors bound by DA and receptors bound by RAC, respectively. \(F_{DA}\) is the free DA concentration, \(K_{D,DA}\) is the dissociation constant for DA at D2R, and fractional occupancies are denoted by \(\theta_{DA}\) and \(\theta_{RAC}\). A solution for the free DA concentration should account both for displacement of bound DA into the free pool and for release of additional DA due to RAC binding presynaptic D2 autoreceptors. We assume the latter process occurs in proportion to RAC occupancy:

\[
F_{DA} = f_{DA}^{(0)} + B_{DA}^{(0)} - B_{DA} + \delta \theta_{RAC}
\]

\[
= K_{D,DA} \frac{\theta_{DA}^{(0)}}{1 - \theta_{DA}^{(0)}} + B_{max} (\theta_{DA}^{(0)} - \theta_{DA}) + \delta \theta_{RAC}, \quad \text{[S2]}
\]

We can employ Eqs. S1 and S2 to relate \(\theta_{DA}\) and \(\theta_{RAC}\) under several scenarios:

i) If we assume the free pool is large in comparison to the bound pool and we ignore RAC-induced DA release, this is equivalent to ignoring the second and third terms in Eq. S2. Under these conditions, the change in DA occupancy \(\Delta \theta_{DA} = \theta_{DA} - \theta_{DA}^{(0)}\) is proportional to RAC occupancy and DA occupancy, and we refer to this model as the linear approximation in the main text:

\[
\Delta \theta_{DA} = - \theta_{RAC} \theta_{DA}^{(0)}. \quad \text{[S3]}
\]

ii) If we ignore RAC-induced DA release but conserve free plus bound dopamine by including the second term in [S2], then the relationship in [S3] deviates only subtly from linearity using literature parameters (Fig. S5). Reported values for \(B_{max}\) in striatum for humans and nonhuman primates (NHPs) are about 20 nM (2, 3) and the \(K_{D,DA}\) for D2R has been estimated to be about 100 nM (4). Although this model produces a relationship between RAC and DA occupancies that is not strictly linear, there is no meaningful difference between this model and the linear approximation.

iii) To include the effect of DA release due to antagonism of autoreceptors, we must rely upon data from rats, where i.p. injection of a dose slightly larger than the maximal dose used in this study produced an approximate doubling of extracellular DA (5). Under these conditions, the relationship between RAC and DA occupancies is described by a quadratic equation that deviates from linearity at middle occupancies (Fig. S5). This model produces a superlinear relationship between DA and RAC occupancies.

Negative changes in DA occupancy are plotted on the y axis in Fig. S5 to provide plots comparable to those in Fig. 5. The three curves correspond to the three assumptions above. Fitting a power function \(a(\theta_{RAC})^{b}\) to the superlinear relation that assumes additional DA release (Fig. S5, red curve), gives an exponent of \(b = 1.6\). This value is very similar to experimental values we observed in Fig. 5. Thus, one interpretation of Fig. 5 is that a superlinear relationship between RAC occupancy and functional magnetic resonance imaging (fMRI) signal results from a superlinear relationship between RAC occupancy and changes in DA occupancy, together with a linear relationship between DA occupancy and the fMRI response.

Occupancy and Dynamic Binding Potential

Binding potential relative to a nondisplaceable tissue compartment \(\text{DBP}_N\) is defined in terms of the available concentration of receptors for binding \(\theta_{DA}^{(0)}\) relative to the dissociation constant \(K_{D}\), scaled by the fraction of ligand that is freely dissolved in tissue water (6). For this study, \(B_{avail}\) is equal to the total density of receptors \(B_{max}\) reduced by the fraction occupied by DA \(\theta_{DA} = B_{DA}/B_{max}\) and RAC \(\theta_{RAC}\). Consequently, the absolute change \(\Delta \text{DBP}_N\), relative to a tracer dose \(\text{DBP}_{N0}\), can be expressed in terms of occupancies:

\[
\frac{\Delta \text{DBP}_N}{\text{DBP}_{N0}} = \frac{(1 - \theta_{DA}^{(0)}) - (1 - \theta_{DA} - \theta_{RAC})}{1 - \theta_{DA}^{(0)}} \quad \text{[S4]}
\]

In all notations, \(\theta\) denotes the theoretical occupancy of DA or RAC, whereas \(\theta^{(0)}\) denotes the measured occupancy value derived from positron-emission tomography (PET) imaging data. The superscript \(0\) denotes basal DA conditions. The change in DA occupancy can be related to RAC occupancy from Eq. S3, so that the fractional change in \(\text{DBP}_N\) becomes an index of RAC occupancy:

\[
\hat{\theta}_{RAC} = \frac{\Delta \text{DBP}_N}{\text{DBP}_{N0}} \approx \theta_{RAC}. \quad \text{[S5]}
\]

All computations of \(\text{DBP}_N\) or the related “dynamic” binding potential \(\text{DBP}_{N0}\) were performed within the framework...
of the simplified reference tissue model (SRTM) (7). In differential form, the time derivative of a tissue time-activity curve (TAC) \( C_T \) can be written in terms of a reference region concentration \( C_{\text{REF}} \), an index \( R_1 \) of the extraction-flow product relative to the reference region, a time constant for outflow from the reference region into plasma \( (k_2) \), and the binding potential \( (BP_{\text{ND}}) \) as

\[
\dot{C}_T = R_1 \dot{C}_{\text{REF}} + k_2 C_{\text{REF}} - k_{2a} C_T
\]

\[
= R_1 \dot{C}_{\text{REF}} + R_1 k_2 C_{\text{REF}} - \frac{R_1 k_2}{1 + BP_{\text{ND}}} C_T. \tag{S6}
\]

Although analytical solutions (7) or general linear model (GLM) techniques (8, 9) often solve for three local parameters, the reference region rate constant \( (k_2) \) is a global parameter, and thus Eq. S4 contains an extra degree of freedom for each voxel or region of interest (ROI) (10). Two questions arise regarding the determination of an appropriate index of occupancy for comparison with a dynamic fMRI response like CBV(t):

i) Should we employ a steady-state analysis based upon \( BP_{\text{ND}} \), even though physiology clearly is changing? \( BP_{\text{ND}} \) represents a weighted average across the 90-min measurement interval, and the weighting function changes vs. the injected mass dose. A dynamic index of receptor availability might offer a less biased alternative. A dynamic binding potential \( (DBP_{\text{ND}}, \text{Eq. 3}) \) is a temporal analog of \( BP_{\text{ND}} \) that is determined in analysis by including a temporal dependence in parameter \( k_{2a}(t) \) (8).

ii) Should we fix parameter \( k_2 \) or employ the original three-parameter SRTM? From inspection, it is clear that \( k_2 \) will be biased toward zero to reduce noise from the last two terms when \( BP \) is small, and this bias should affect other parameters as well. Because specific binding varies with mass dose, a three-parameter model may exhibit more bias vs. mass.

On the basis of this reasoning, we employed a standard steady-state \( BP_{\text{ND}} \) analysis with a two-parameter SRTM and a dynamic analysis by adding a time-dependent \( k_{2a}(t) \) term. A comparison of the two model fits is shown in Fig. S2 for the 16 mg/kg dataset in animal M2. The dynamic analysis provides a better fit visually and is based on \( \chi^2/DOF \) values, which are \( 2.8 \times 10^6 \) and \( 0.7 \times 10^6 \) for the SRTM and dynamic analysis, respectively.

**Forward-Model Simulation and Analysis**

This section describes simulations that (i) investigated the accuracy of SRTM estimates of occupancy using the confusion paradigm employed in this study and (ii) compared simplified estimates of specific binding based upon SRTM with actual specific binding in a simulation model with separate free and specifically bound compartments.

Because our experimental paradigm used progressively larger doses of RAC to reduce \( BP_{\text{ND}} \), we investigated the accuracy of linear SRTM measurements of occupancy as a function of RAC dosage, using forward-model simulations, which included compartments for plasma, free, and specifically bound RAC and free and specifically bound DA (3). Literature values were employed for all rate constants, dissociation constants, and the concentration of D2R (Table S1). Plasma kinetics were approximated by a gamma-variate profile for RAC injection followed by biexponential decay of RAC from plasma; these kinetics were adjusted to match the reference region TAC from experimental data. Synthetic noise (11) was applied to TACs to approximate experimental data from basal ganglia ROIs. Because simulations separated free and specifically bound compartments, true values for specific binding were known as a function of time. Hence, we could assess the accuracy of SRTM analyses based upon \( BP_{\text{ND}} \) values vs. that based on time-dependent binding models.

We analyzed simulated data by the GLM, using the same software that was employed to analyze real data. Analyses used the integral form of [S6] and either three local constant parameters (8), or two local parameters (12). Additionally, we evaluated the effect of a time-dependent \( k_{2a} \) (following ref. 8). The time dependence was implemented as a gamma-variate function specified by a single parameter defining the time to peak \( \tau \). Thus, SRTM included either three or four local parameters, and the reduced model [multilinear reference tissue model (MRTM2)] included a global value for \( k_2 \) \((k_{2a})\) and either two or three local parameters, with the latter version explicitly formulated as

\[
C_T(t) = R_1 \left( C_{\text{REF}} + k_{2a} \int C_T(t) dt \right) - k_{2a} \int C_T(t) dt - k_{2a} \int \gamma(t, \tau) C_T(t) dt, \tag{S7}
\]

where

\[
\gamma(t, \tau) = (\tau/\tau_t)^{\left(1-\tau/\tau_t\right)}
\]

When employing a time-dependent \( k_{2a} \) term, the time-to-peak parameter was determined in two different ways to determine the sensitivity of results to the choice of the time constant \( \tau \): (i) by minimizing the \( \chi^2/DOF \) of the GLM fit to data for each dose or (ii) by minimizing the \( \chi^2/DOF \) for the lowest dose and maintaining that value of \( \tau \) for all doses.

The main simulation results are summarized in Fig. S3. The conventional SRTM model produced estimates of RAC occupancies that underestimated true peak occupancies by 10–15% at high doses (black squares). Best results were obtained by adding a gamma time dependence to MRTM2 (red circles) in which the variable \( \tau \) was optimized for each dose. Errors in occupancy were <2% at all doses. Intermediate results with up to 7% error were obtained by using fixed values of \( \tau \), based upon fits within MRTM2 for data at the lowest mass dose. Fitting up to four parameters (SRTM with a gamma time dependence on \( k_{2a} \) did not provide stable estimates of \( \tau \) across doses within simulations.

These results suggest that the most accurate method for determining peak changes in RAC occupancies in this confusion paradigm is to (i) fit parameter \( k_2 \) in a high-binding region (e.g., putamen) at low mass dose, (ii) eliminate the extra degree of freedom incorporated into the three-parameter SRTM model by fixing \( k_2 \), and (iii) add a time-dependent binding term that is optimized at each dose by minimizing the \( \chi^2/DOF \) in a high-binding region (e.g., putamen).

In a full reference tissue model (FRTM) (13), specific binding is known, whereas SRTM analysis determines only the ratio of the rate constants \( (k_1, k_4) \) between the free and specifically bound compartments, as well as an effective rate constant \( (k_{2a}) \) for washout. In measurements and fits, the offset rate constant \( (k_2) \) has been determined to be about 3–10 times smaller than the washout rate constant (3, 14), so that the free and nonspecifically bound compartment changes much more rapidly in time than the specifically bound compartment. Thus, an approximate index of specific binding can be obtained through SRTM by correcting the tissue concentration TAC for ligand delivery and washout by subtracting the reference region and scaling for the relative flow-extraction product \( (R_1) \) as \( C_S = S = C_T - R_1 C_{\text{REF}} \). Fig. S4 compares specific binding \( C_S \) as determined from an analysis with the FRTM to the specific binding estimate \( S \). In both cases, the peak of \( S \) is shifted by no more than a few minutes compared to that of \( C_S \), which is compatible with the uncertainty in the time-to-peak response of fMRI signal and PET-specific binding in this study based upon optimization of the \( \chi^2/DOF \), as described in Results.


---

**Fig. S1.** Simulations of a multicompartmental model based upon first-order kinetics: Specific binding of raclopride vs. time and for increasing dose, normalized to the maximum value to observe differences in shape due to receptor saturation.

**Fig. S2.** Comparison of an SRTM fit (black line) with a dynamic fit (red line) that allows the use of $DBP_{ND}$ for the 16 μg/kg RAC mass dose in M2. The dynamic method shows an improved fit visually and by $\chi^2$/DOF measures.
Fig. S3. Analysis of simulated data to determine the accuracy of occupancy estimates relative to true peak change in occupancy. Simulations were analyzed within the SRTM framework by GLM: Conventional three-parameter SRTM analyses with a fixed \( BP_0 \) (black squares) systematically underestimate peak occupancy, whereas the two-parameter SRTM (red circles) accurately determines peak occupancy when a gamma-variate function is embedded in parameter \( k_2 \).

Fig. S4. Estimate of specific binding computed from the data (\( S = C_T - R_1 C_{REF} \), solid black line) compared with specific binding (dashed blue line) modeled with a full reference tissue model based on fitted parameters for the two highest RAC mass doses in M1 (16 \( \mu g/kg \) and 40 \( \mu g/kg \)).
Fig. S5. Relationship between the fractional occupancies of raclopride ($\theta_{\text{RAC}}$) and the change in fractional occupancy of DA ($\Delta\theta_{\text{DA}}$), which drives the fMRI signal, using the linear approximation of Eq. S3 (dashed black line) or estimating effects of DA displacement (solid blue line) and displacement plus release (solid red line). Calculations assume a 20% basal DA occupancy.

Table S1. Parameters used in forward-model simulations

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Species</th>
<th>Source or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>$B_{\text{max}}$</td>
<td>17 nM</td>
<td>NHP</td>
<td>Endres et al. (1997) (1)</td>
</tr>
<tr>
<td>$K_D$</td>
<td>3.8 nM</td>
<td>Human</td>
<td>Farde et al. (1986) (2)</td>
</tr>
<tr>
<td>$\theta_{DA}$ in basal state</td>
<td>25%</td>
<td>Human</td>
<td>Verhoeff et al. (2002) (3)</td>
</tr>
<tr>
<td>BPND</td>
<td>3.36</td>
<td>NHP</td>
<td>From $B_{\text{max}}$, $K_D$, and $\theta_{DA}$</td>
</tr>
<tr>
<td>$K_1$</td>
<td>0.17 min$^{-1}$</td>
<td>NHP</td>
<td>Endres et al. (1997) (1)</td>
</tr>
<tr>
<td>$V_D$, distribution volume in</td>
<td>0.7</td>
<td>NHP</td>
<td>Endres et al. (1997) (1)</td>
</tr>
<tr>
<td>reference region</td>
<td></td>
<td></td>
<td>Measured from data</td>
</tr>
<tr>
<td>$K_{D,DA}$</td>
<td>100 nM</td>
<td>Human</td>
<td>Fisher et al. (1995) (4)</td>
</tr>
<tr>
<td>$k_4,DA = k_{\text{off},DA}$</td>
<td>1 min$^{-1}$</td>
<td>NHP</td>
<td>Logan et al. (2001) (5)</td>
</tr>
<tr>
<td>$k_a = k_{\text{off},RAC}$</td>
<td>0.07 min$^{-1}$</td>
<td>NHP</td>
<td>Endres et al. (1997) (1)</td>
</tr>
</tbody>
</table>